• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Meta-analysis: Do Combined Oral Contraceptives Relieve Premenstrual Depressive Symptoms?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Combined oral contraceptives are often used as treatment for women with premenstrual syndrome (PMS) or premenstrual dysphoric disorder (PMDD) but data on efficacy is limited
  • In a review and meta-analysis, de Wit et al. (AJOG, 2021) assessed the efficacy of combined oral contraceptives in managing premenstrual depressive symptoms

METHODS:

  • Systematic review and meta-analysis
  • Inclusion criteria
    • RCTs
    • Studies that evaluated the efficacy of combined oral contraceptives in women with PMS or PMDD
  • Study design
    • Random effect Bayesian pairwise and network meta-analysis
    • Certainty of evidence was assessed using GRADE criteria
  • Primary outcome
    • Change in premenstrual depressive symptoms and overall premenstrual symptomatology between baseline and 3 cycles

RESULTS:

  • 9 trials | 1205 women
    • Mean age: 24.6 to 36.5 years
  • Combined oral contraceptives were more efficacious than placebo in treating overall premenstrual symptomatology
    • Standardized mean difference 0.41 (95% CI, 0.17 to 0.67)
  • Combined oral contraceptives did not have a significant effect on premenstrual depressive symptoms specifically
    • Standardized mean difference 0.22 (95% CI, -0.06 to 0.47)
  • None of the combined oral contraceptives were more effective than others in reducing premenstrual depressive symptoms and overall premenstrual symptomatology

CONCLUSION:

  • The use of combined oral contraceptives may improve overall premenstrual symptoms for those with PMS or PMDD, but not premenstrual depressive symptoms
  • No one type of combined oral contraceptive was superior to another for symptom reduction
  • The authors state

In women who predominantly complain about depressive symptoms, other commonly used treatment options for women with PMDD, such as selective serotonin reuptake inhibitors and cognitive-behavioral therapy, might be a more effective approach

In contrast to what is often thought, there was no evidence for a difference in efficacy among formulations containing drospirenone and other formulations or a 24-day regimen vs other regimens

Learn More – Primary Sources:

Efficacy of combined oral contraceptives for depressive symptoms and overall symptomatology in premenstrual syndrome: pairwise and network meta-analysis of randomized trials

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Does Hormonal Contraceptive Use Lower the Incidence of Severe Asthma Events?
How Do Combined Hormonal Contraceptives Compare to Other Treatments for Menorrhagia?
Different Methods of Contraception and Their Impact on Severity and Incidence of Acne
Cochrane Review 2020: Are Progestogen-Releasing IUDs Effective for Managing Heavy Menstrual Bleeding?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site